Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SDCBP | O00560 | 4/20 | 0.42 |
| ▸ | SDC2 | P34741 | 4/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18766179 | 1.00 | SDCBP (0.42) | SDCBPSDC2GABRA1GABRG2GABRB3 | |
| SCHEMBL18794099 | 1.00 | SDCBP (0.42) | SDCBPSDC2GABRA1GABRG2GABRB3 | |
| SCHEMBL18766178 | 1.00 | SDCBP (0.42) | SDCBPSDC2GABRA1GABRG2GABRB3 | |
| SCHEMBL17141805 | 0.86 | SDCBP (0.46) | SDCBPSDC2THRBNPC1RAB9A | |
| SCHEMBL18794101 | 0.85 | THRB (0.38) | SDCBPSDC2THRBNPC1RAB9A | |
| SCHEMBL18793367 | 0.85 | NPC1 (0.40) | SDCBPSDC2GABRA1GABRG2GABRB3 | |
| SCHEMBL25921075 | 0.85 | NPC1 (0.40) | SDCBPSDC2GABRA1GABRG2GABRB3 | |
| SCHEMBL18765504 | 0.82 | SDCBP (0.52) | SDCBPSDC2THRBALDH1A1ALOX15 | |
| SCHEMBL18765599 | 0.82 | SDCBP (0.52) | SDCBPSDC2THRBALDH1A1ALOX15 | |
| SCHEMBL2179112 | 0.82 | SDCBP (0.52) | SDCBPSDC2THRBALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114948963-B | Benzolactam compounds as protein kinase inhibitors | 大冢制药株式会社 | 2025-05-27 | — | — | CN | disclosed |
| CN-110831939-B | 6-Pyrimidine-isoindole derivatives as ERK1/2 inhibitors | 大冢制药株式会社 | 2025-05-09 | — | — | CN | disclosed |
| US-20250002481-A1 | 6-PYRIMIDIN-ISOINDOLE DERIVATIVE AS ERK1/2 INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-01-02 | — | — | US | disclosed |
| US-20240287051-A1 | PROCESS FOR PREPARING AN ERK INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-08-29 | — | — | US | disclosed |
| EP-3612524-B1 | 6-PYRIMIDIN-ISOINDOLE DERIVATIVE AS ERK1/2 INHIBITOR | OTSUKA PHARMA CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| US-12030873-B2 | 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-07-09 | — | — | US | disclosed |
| EP-4352052-A1 | PROCESS FOR PREPARING AN ERK INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022259222-A1 | PROCESS FOR PREPARING AN ERK INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-12-15 | — | — | WO | disclosed |
| CN-114948963-A | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-08-30 | — | — | CN | disclosed |
| US-20220169638-A1 | 6-PYRIMIDIN-ISOINDOLE DERIVATIVE AS ERK1/2 INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-06-02 | — | — | US | disclosed |
| CN-108617166-B | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-05-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002481-A1 | 6-PYRIMIDIN-ISOINDOLE DERIVATIVE AS ERK1/2 INHIBITOR | MAPKAPK2, MAP4K2, MAPK1 | SDCBP 4450/4885SDC2 4030/4885GABRA1 1678/4885 |
| US-12030873-B2 | 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor | MAPKAPK2, MAP4K2, MAPK1 | SDCBP 4450/4885SDC2 4030/4885GABRA1 1678/4885 |
| US-20240287051-A1 | PROCESS FOR PREPARING AN ERK INHIBITOR | MAP3K8, MAP3K1, MAP3K6 | SDCBP 2946/4885SDC2 3525/4885GABRA1 4165/4885 |
| US-20220169638-A1 | 6-PYRIMIDIN-ISOINDOLE DERIVATIVE AS ERK1/2 INHIBITOR | MAPKAPK2, MAP4K2, MAPK1 | SDCBP 4450/4885SDC2 4030/4885GABRA1 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.